Zai Lab (NASDAQ:ZLAB) Announces Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Posted by Stanley Muller on Mar 1st, 2025

Zai Lab (NASDAQ:ZLAB – Get Free Report) issued its earnings results on Thursday. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19), Zacks reports. The company had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. Zai Lab updated its FY 2025 guidance to EPS.

Zai Lab Trading Up 0.8 %

Zai Lab stock opened at $34.64 on Friday. Zai Lab has a 1-year low of $13.48 and a 1-year high of $36.60. The firm has a market capitalization of $3.79 billion, a price-to-earnings ratio of -12.51 and a beta of 1.02. The firm’s fifty day moving average price is $27.51 and its two-hundred day moving average price is $25.69.

Insider Buying and Selling at Zai Lab

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total value of $199,281.24. Following the transaction, the insider now directly owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. This trade represents a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 13.88% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald raised shares of Zai Lab to a “strong-buy” rating in a research note on Wednesday, February 5th.

Get Our Latest Analysis on ZLAB

Zai Lab Company Profile

(Get Free Report)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.